Skirting a group of pioneers, Gilead partners with gene-editing upstart Precision Bio in hunt to cure hep B
Having already found a painless cure for hepatitis C, Gilead has now set its sights on another cure for hepatitis B. And they’ve steered around the most prominent gene-editing players in the field to partner up Durham, NC-based Precision BioSciences just a couple of months after the biotech raised an impressive $110 million mega-crossover round.
Gilead said this morning it has seeded their collaboration with Precision with $445 million in milestones, avoiding any mention of an upfront in the announcement.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.